Ketoacidosis

Disclaimer: This document provides general medical information for educational purposes only and does not constitute medical advice. It is intended for healthcare professionals as a reference and should not be used as a substitute for professional medical judgment. Clinical decisions must always be made based on the individual patient's condition, available evidence, and the clinician's expertise. Current guidelines and local protocols should always be consulted.

Overview

• Definition: Ketoacidosis is a severe metabolic derangement characterized by hyperglycemia (usually), metabolic acidosis, and high circulating ketone bodies, primarily beta-hydroxybutyrate (BHB). The most common and clinically significant form is Diabetic Ketoacidosis (DKA), which occurs due to an absolute or relative insulin deficiency compounded by increased counter-regulatory hormones. Other forms include Alcoholic Ketoacidosis (AKA) and Starvation Ketoacidosis.
• Epidemiology:
  • Diabetic Ketoacidosis (DKA):
    • Incidence: Approximately 1-10 episodes per 100 patient-years in Type 1 Diabetes Mellitus (T1DM).
    • Accounts for 4-9% of all hospital admissions for diabetes.
    • Most common in T1DM, but can occur in Type 2 Diabetes Mellitus (T2DM) under severe stress (e.g., sepsis, pancreatitis, stroke, myocardial infarction) - termed "ketosis-prone T2DM."
    • Higher incidence in younger patients with T1DM, those with poor glycemic control, and individuals with psychiatric comorbidities or eating disorders.
  • Alcoholic Ketoacidosis (AKA): Common in chronic alcohol abusers, often presenting after a binge followed by decreased oral intake.
  • Starvation Ketoacidosis: Less common and typically less severe, occurring after prolonged fasting or severe calorie restriction.
• Classification:
  • Diabetic Ketoacidosis (DKA):
    • Mild DKA: pH 7.25-7.30, HCO3 15-18 mEq/L, Anion Gap >10-12, Glucose >250 mg/dL (13.9 mmol/L).
    • Moderate DKA: pH 7.00-7.24, HCO3 10-<15 mEq/L, Anion Gap >12, Glucose >250 mg/dL (13.9 mmol/L).
    • Severe DKA: pH <7.00, HCO3 <10 mEq/L, Anion Gap >12, Glucose >250 mg/dL (13.9 mmol/L).
    • Euglycemic DKA (euDKA): Characterized by metabolic acidosis and ketonemia in the setting of normal or near-normal glucose levels (<250 mg/dL). Increasingly seen with SGLT2 inhibitor use.
  • Hyperosmolar Hyperglycemic State (HHS): While not strictly ketoacidosis (minimal ketosis), it's a related hyperglycemic crisis often seen in T2DM. Characterized by severe hyperglycemia (>600 mg/dL), hyperosmolality (>320 mOsm/kg), and profound dehydration, with only mild or absent ketosis/acidosis. Overlap between DKA and HHS can occur (mixed picture).
  • Alcoholic Ketoacidosis (AKA): Typically normo- or hypoglycemic, with elevated anion gap metabolic acidosis and ketonemia (often predominated by acetone and acetoacetate initially, with BHB increasing after fluid administration).
  • Starvation Ketoacidosis: Mild ketonemia, mild acidosis, and mild hypoglycemia, typically not associated with severe illness.

Pathophysiology

• Mechanism:
  • Insulin Deficiency/Resistance: Absolute lack of insulin (T1DM, insulin non-adherence) or relative deficiency/resistance (stress, infection, T2DM). This leads to impaired glucose utilization by peripheral tissues and unrestrained hepatic glucose production (glycogenolysis and gluconeogenesis), resulting in hyperglycemia.
  • Counter-Regulatory Hormone Excess: Elevated levels of glucagon, cortisol, catecholamines, and growth hormone counteract insulin's effects and promote hyperglycemia and lipolysis.
  • Lipolysis and Ketogenesis: Lack of insulin, combined with high levels of catecholamines and glucagon, activates hormone-sensitive lipase. This causes a massive breakdown of triglycerides in adipose tissue, releasing large quantities of free fatty acids (FFAs) into the circulation.
  • FFAs are transported to the liver, where, in the absence of adequate insulin and presence of high glucagon, they undergo accelerated β-oxidation to acetyl-CoA.
  • Acetyl-CoA is shunted into ketogenesis instead of the Krebs cycle, producing acetoacetate, beta-hydroxybutyrate (BHB), and acetone. BHB is the predominant ketone body in DKA.
  • Metabolic Acidosis: Acetoacetate and BHB are strong organic acids. Their accumulation in the blood overwhelms the body's buffer systems, leading to a high anion gap metabolic acidosis.
  • Osmotic Diuresis: Severe hyperglycemia causes osmotic diuresis, leading to significant fluid and electrolyte losses (sodium, potassium, phosphate). This results in profound dehydration, hypovolemia, and electrolyte imbalances.
• Risk Factors:
  • New-onset Type 1 Diabetes: Often the initial presentation.
  • Insulin Omission/Non-adherence: Common in established diabetes.
  • Infection: Pneumonia, urinary tract infection, sepsis (most common precipitating factor).
  • Acute Illness/Stress: Myocardial infarction, stroke, pancreatitis, trauma, surgery, burns.
  • Endocrine Disorders: Cushing's syndrome, acromegaly, hyperthyroidism.
  • Medications: Corticosteroids, thiazide diuretics, atypical antipsychotics, sympathomimetics.
  • SGLT2 Inhibitors: Can cause euglycemic DKA due to increased glucagon, ketogenesis, and glycosuria (leading to fluid depletion and hemoconcentration).
  • Eating Disorders/Psychiatric Illness: Insulin omission for weight loss.
  • Alcohol Abuse: Leading to AKA due to glycogen depletion, impaired gluconeogenesis, and elevated counter-regulatory hormones.
• Protective Factors:
  • Optimal Diabetes Education: Understanding sick-day management, insulin adjustment, and blood glucose monitoring.
  • Adherence to Insulin Regimen: Consistent and correct insulin administration.
  • Frequent Blood Glucose Monitoring: Early detection of hyperglycemia and ketosis.
  • Prompt Management of Intercurrent Illnesses: Seeking medical attention for infections or other stressors.
  • Adequate Hydration: Especially during illness to minimize dehydration.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Polyuria and Polydipsia: Due to osmotic diuresis from hyperglycemia.
  • Nausea, Vomiting, Abdominal Pain: Common, often severe and can mimic acute abdomen.
  • Fatigue, Weakness, Lethargy: General malaise.
  • Kussmaul Respirations: Deep, rapid breathing, an attempt to compensate for metabolic acidosis (blow off CO2).
  • Fruity Breath Odor: Due to acetone (volatilized ketone body).
  • Altered Mental Status: Ranging from confusion to coma, correlated with severity of acidosis and hyperosmolality.
• Early Signs:
  • Polyuria, polydipsia
  • Increased thirst
  • Fatigue, malaise
  • Headache
  • Blurred vision
• Advanced Signs:
  • Severe nausea, persistent vomiting
  • Severe abdominal pain
  • Kussmaul respirations
  • Significant dehydration (dry mucous membranes, sunken eyes, poor skin turgor)
  • Hypotension, tachycardia (due to hypovolemia)
  • Altered consciousness (lethargy, stupor, coma)
  • Fruity breath
• Atypical Presentations:
  • Euglycemic DKA: Glucose <250 mg/dL, often precipitated by SGLT2 inhibitors, pregnancy, prolonged fasting, or alcohol. Patients may not present with classic polyuria/polydipsia.
  • Predominant Abdominal Pain: Can lead to misdiagnosis as acute appendicitis, pancreatitis, or cholecystitis.
  • Normal Mental Status with Severe Acidosis: Possible in early stages, or if acidosis compensated by respiratory effort.
  • AKA: Often normo- or hypoglycemic, history of binge drinking, minimal polyuria/polydipsia.

Physical Examination

• Inspection:
  • Signs of dehydration: Dry mucous membranes, decreased skin turgor, sunken eyeballs.
  • Respiratory pattern: Kussmaul respirations (deep, rapid, sighing).
  • Mental status: Alert, lethargic, obtunded, or comatose.
  • Signs of precipitating illness: Fever (infection), signs of trauma, abdominal distension, surgical scars, etc.
• Palpation:
  • Abdominal tenderness (diffuse or localized).
  • Pulse: Tachycardia, weak or thready peripheral pulses (hypovolemia).
  • Skin: Cool, clammy (shock) or warm and dry (dehydration).
• Special Tests:
  • Neurological examination: Assess level of consciousness, pupillary response, and motor function, especially if cerebral edema is suspected (e.g., in pediatric DKA).
  • Cardiac auscultation: Assess for signs of fluid overload or underlying cardiac disease.
  • Pulmonary auscultation: Assess for signs of pneumonia (rales, rhonchi).

Diagnostic Approach

History Taking

• Key Questions:
  • Duration and severity of symptoms: Polyuria, polydipsia, nausea, vomiting, abdominal pain, fatigue, weight loss.
  • Diabetes history: Type of diabetes, duration, usual insulin regimen (type, dose, frequency), adherence, recent changes.
  • Precipitating factors: Recent illness (fever, cough, dysuria), infection (UTI, pneumonia, skin infection), non-adherence to insulin or diet, recent stress (MI, stroke, surgery), alcohol intake, medications (especially new ones like SGLT2 inhibitors, steroids).
  • Sick-day management: Did the patient follow sick-day rules (e.g., continue insulin, monitor blood glucose/ketones)?
  • Past DKA episodes: Frequency, causes, and previous management.
  • Comorbidities: Heart failure, renal disease, hypertension, etc., which might influence fluid management.
• Red Flags:
  • Persistent vomiting (inability to tolerate oral fluids).
  • Altered mental status (lethargy, confusion, stupor).
  • Signs of severe dehydration or shock (hypotension, tachycardia).
  • High fever or signs of severe infection.
  • Significant abdominal pain.

Laboratory Tests

• First-Line:
  • Blood Glucose: Point-of-care (fingerstick) and laboratory serum glucose. Typically >250 mg/dL (13.9 mmol/L) in DKA, but can be lower in euDKA.
  • Urinalysis: For glucose and ketones. Urine dipstick primarily detects acetoacetate. A negative urine ketone does not rule out DKA, as BHB is the predominant ketone.
  • Electrolytes (Na, K, Cl, HCO3): Calculate corrected sodium (for hyperglycemia: add 1.6 mEq/L to measured Na for every 100 mg/dL increase in glucose over 100 mg/dL). Crucial for anion gap calculation and guiding potassium replacement.
  • Serum Creatinine (Cr) and Blood Urea Nitrogen (BUN): Assess renal function and degree of dehydration.
  • Arterial Blood Gas (ABG) or Venous Blood Gas (VBG):
    • pH: <7.30 (mild DKA), <7.25 (moderate), <7.00 (severe). VBG pH is usually 0.02-0.03 units lower than ABG.
    • Bicarbonate (HCO3): <18 mEq/L (mild), <15 mEq/L (moderate), <10 mEq/L (severe).
    • PaCO2: Low due to respiratory compensation.
  • Anion Gap (AG): Calculated as Na - (Cl + HCO3). Normal is 8-12 mEq/L. Anion gap >10-12 mEq/L indicates metabolic acidosis.
  • Serum Ketones: Preferable to urine ketones as they measure BHB directly. A level >3.0 mmol/L is diagnostic for DKA.
  • Complete Blood Count (CBC) with differential: Leukocytosis is common even without infection due to stress response. Significant left shift may indicate infection.
  • Serum Osmolality: Calculated as 2xNa + Glucose/18 + BUN/2.8. Usually elevated, especially in mixed DKA/HHS.
• Confirmatory:
  • Serum Beta-hydroxybutyrate (BHB): The most accurate and preferred test for diagnosing ketosis and monitoring resolution. Levels >3.0 mmol/L confirm DKA.
  • Anion Gap calculation: Essential for confirming high anion gap metabolic acidosis.
• Monitoring:
  • Blood Glucose: Hourly.
  • Electrolytes (Na, K, Cl, HCO3): Every 2-4 hours, or more frequently depending on clinical status and potassium levels.
  • BHB: Every 4-6 hours to monitor resolution of ketosis.
  • ABG/VBG: Periodically to monitor pH and bicarbonate, especially in severe cases, until acidosis resolves.

Imaging

• Recommended:
  • Chest X-ray (CXR): If respiratory symptoms or signs of infection (e.g., fever, cough) are present to rule out pneumonia.
  • Electrocardiogram (ECG): To assess for cardiac ischemia (if chest pain or risk factors) and to monitor for effects of hyperkalemia or hypokalemia (peaked T waves, U waves, flattened T waves, prolonged QT).
  • Urinalysis and Urine Culture: If urinary symptoms or signs of UTI.
• Advanced:
  • Abdominal Imaging (Ultrasound, CT scan): If severe, unexplained abdominal pain, to rule out acute abdomen (e.g., pancreatitis, cholecystitis, appendicitis).
  • Head CT Scan: If neurological signs are prominent, focal, or if mental status does not improve with metabolic correction, especially in pediatric patients where cerebral edema is a risk. Also, if there's suspicion of stroke or other intracranial pathology.

Management

Management of DKA is an emergency requiring hospitalization, often in an intensive care unit (ICU) for severe cases, and a systematic approach focusing on fluid resuscitation, insulin administration, electrolyte correction, and identification/treatment of the precipitating cause.

Acute Management

Goals: Correct dehydration, hyperglycemia, ketoacidosis, and electrolyte imbalances.

• Immediate (First Hour Interventions):
  1. Airway, Breathing, Circulation (ABCs): Assess and stabilize. Provide oxygen if SpO2 <90%.
  2. Fluid Resuscitation: Crucial for restoring circulating volume and lowering glucose.
     • Adults:
       • Initial bolus: 1-1.5 L (or 15-20 mL/kg) of 0.9% Normal Saline (NS) over the first hour. In patients with severe hypovolemic shock, a more rapid bolus may be indicated.
       • Subsequent fluid: 250-500 mL/hour of 0.9% NS, or switch to 0.45% NS at 250-500 mL/hour if corrected serum Na is normal or high.
       • When glucose reaches 200 mg/dL (11.1 mmol/L): Change IV fluids to Dextrose 5% in 0.45% NS (D5NS) at 150-250 mL/hour to prevent hypoglycemia and allow continued insulin to resolve ketosis.
     • Pediatrics: 10-20 mL/kg of 0.9% NS over 1-2 hours. Total fluid deficit should be corrected slowly over 24-48 hours. Close monitoring of neurological status is essential due to risk of cerebral edema.
• Stabilization (Early Management Priorities):
  1. Insulin Therapy:
     • Initiation: Delay insulin infusion until potassium level is known (if K <3.3 mEq/L, give K first).
     • Bolus: No routine bolus recommended, as it increases risk of hypokalemia and cerebral edema, especially in pediatric patients.
     • Continuous IV Insulin Infusion:
       • Adults: 0.1 U/kg/hour regular insulin.
       • Pediatrics: 0.05-0.1 U/kg/hour regular insulin.
       • Goal: Decrease blood glucose by 50-75 mg/dL/hour. If not achieved after 1 hour, double insulin infusion rate.
       • Continue insulin infusion until anion gap closes and bicarbonate normalizes.
  2. Potassium Replacement: DKA often causes total body potassium depletion, even if initial serum K is normal or high.
     • If K <3.3 mEq/L: Hold insulin. Administer 20-40 mEq/hour K until K >3.3 mEq/L.
     • If K 3.3-5.2 mEq/L: Add 20-30 mEq K to each liter of IV fluid to maintain K in the 4-5 mEq/L range. Start insulin.
     • If K >5.2 mEq/L: Do not add K initially, but check K every 2 hours as it will fall rapidly with insulin and fluid.
     • Administer potassium as a mixture of KCl, K-phosphate, or K-acetate.
  3. Bicarbonate Therapy: Generally not recommended for DKA, as it can worsen cerebral edema, shift the oxygen-hemoglobin dissociation curve, and cause rebound alkalosis.
     • Indications: Only considered for severe DKA (pH <6.9-7.0) with life-threatening hyperkalemia or cardiac instability (e.g., severe dysrhythmias, impaired myocardial contractility).
     • Dosage (if indicated): 100 mmol sodium bicarbonate in 400 mL sterile water with 20 mEq KCl given over 2 hours.
  4. Phosphate Replacement: Not routinely recommended. Total body phosphate is depleted, but serum levels are often normal or high due to shifting.
     • Indications: Only if serum phosphate <1.0 mg/dL AND cardiac dysfunction, respiratory depression, or hemolytic anemia.
     • Dosage: 20-30 mmol K-phosphate can be added to replacement fluids.
  5. Identify and Treat Precipitating Cause: Administer broad-spectrum antibiotics if infection is suspected. Treat MI, stroke, or other acute conditions.
• Emergency (Crisis Management):
  • Hypovolemic Shock: Aggressive fluid boluses (e.g., 500-1000 mL 0.9% NS over 15-30 minutes) and consider vasopressors if hypotension persists despite adequate fluid resuscitation.
  • Severe Electrolyte Abnormalities:
    • Hyperkalemia: Calcium gluconate, insulin/glucose, bicarbonate, beta-agonists, diuretics, dialysis.
    • Severe Hypokalemia: See above (K <3.3 mEq/L protocol).
  • Cerebral Edema: A life-threatening complication, especially in children.
    • Signs: Headache, lethargy, decreased level of consciousness, bradycardia, hypertension, papilledema, cranial nerve palsies.
    • Management: Reduce IV fluids, administer mannitol (0.5-1 g/kg IV over 20 minutes) or hypertonic saline (3% NaCl, 5-10 mL/kg over 30 minutes). Head CT to confirm.

Chronic Management

• Transition to Subcutaneous Insulin:
  • DKA is resolved when blood glucose is <200 mg/dL (11.1 mmol/L), anion gap <12 mEq/L, and bicarbonate >15 mEq/L.
  • Overlap IV insulin with subcutaneous insulin by 1-2 hours to prevent rebound ketosis.
  • Calculate total daily insulin dose based on patient's usual dose or starting with 0.5-0.8 U/kg/day, divided into basal and bolus components.
  • Provide patient education on sick-day management.
• Pharmacological:
  • Insulin: Tailor regimen (multiple daily injections or insulin pump) to maintain glycemic control and prevent recurrence.
  • Oral Hypoglycemic Agents: If Type 2 Diabetes, consider re-introduction of oral agents after DKA resolution, carefully assessing for persistent ketosis or need for basal insulin. Patients with ketosis-prone T2DM often require insulin long-term.
  • Review all medications: Discontinue or adjust medications that can precipitate DKA (e.g., high-dose steroids, SGLT2 inhibitors if not indicated or patient at high risk).
• Non-pharmacological:
  • Comprehensive Diabetes Education: Crucial for preventing recurrence.
    • Sick-day management plan: How to adjust insulin during illness, when to check ketones, when to seek medical attention, ensuring adequate fluid and carbohydrate intake.
    • Importance of insulin adherence.
    • Dietary management.
    • Stress management.
  • Psychological Support: For patients with eating disorders or non-adherence issues.
• Monitoring:
  • Regular follow-up with endocrinology.
  • HbA1c monitoring.
  • Review of blood glucose logs and ketone testing habits.
  • Reinforce sick-day rules at every visit.

Treatment Algorithms

A simplified DKA management algorithm:

1. Initial Assessment & Resuscitation (Hour 0-1)
   • ABCs: Assess airway, breathing, circulation. O2 if needed.
   • Fluids: 1000-1500 mL (15-20 mL/kg) 0.9% NS IV bolus over the first hour.
   • Labs: Obtain baseline glucose, electrolytes (with corrected Na), BUN, Cr, ABG/VBG, serum ketones (BHB), CBC, UA.
   • Potassium Check: Crucial step before insulin.
2. Ongoing Management (Hours 1+)
   • Potassium Replacement:
     • If K <3.3 mEq/L: Give 20-40 mEq KCl/hour. HOLD INSULIN until K >3.3.
     • If K 3.3-5.2 mEq/L: Add 20-30 mEq K to each liter of IV fluid. START INSULIN.
     • If K >5.2 mEq/L: No K initially. Monitor K every 2 hours. START INSULIN.
   • Insulin Infusion: Start continuous IV regular insulin at 0.1 U/kg/hour.
   • Fluid Management:
     • After initial bolus, continue 0.9% NS at 250-500 mL/hour or switch to 0.45% NS if corrected Na is normal/high.
     • When blood glucose reaches 200 mg/dL (11.1 mmol/L): Change IV fluids to Dextrose 5% in 0.45% NS (D5NS) at 150-250 mL/hour. Continue insulin infusion at the same rate, or decrease to 0.05-0.1 U/kg/hour, to allow resolution of ketosis.
   • Bicarbonate: Rarely indicated. Only for pH <6.9-7.0 with cardiac instability or life-threatening hyperkalemia.
   • Phosphate: Only if severe hypophosphatemia (<1.0 mg/dL) with specific clinical manifestations.
   • Monitor: Glucose hourly. Electrolytes (Na, K, Cl, HCO3), BHB, and pH every 2-4 hours.
   • Identify and Treat Precipitating Cause.
3. Resolution & Transition to Subcutaneous Insulin:
   • Criteria for Resolution: Blood glucose <200 mg/dL, anion gap <12 mEq/L, and bicarbonate >15 mEq/L (or BHB <1.0 mmol/L and normal anion gap).
   • Transition: Start patient on subcutaneous insulin 1-2 hours before discontinuing IV insulin infusion.
   • Education: Reinforce sick-day rules and prevention strategies.

Complications

• Common:
  • Hypoglycemia: Due to over-aggressive insulin therapy, especially during transition to oral intake/subcutaneous insulin.
  • Hypokalemia: With insulin administration and fluid repletion. Most common and potentially life-threatening electrolyte disturbance during DKA treatment.
  • Hyperglycemia: If insulin or fluids are not adequately managed.
  • Fluid Overload/Pulmonary Edema: Especially in patients with underlying cardiac or renal dysfunction, or overly aggressive fluid resuscitation.
  • Rebound Ketosis: If IV insulin is stopped too soon or subcutaneous insulin not started properly.
• Serious:
  • Cerebral Edema: A devastating complication, particularly in children and young adults (0.5-1% of DKA cases), with high mortality (20-40%) and morbidity. Risk factors include rapid fluid administration, rapid glucose correction, bicarbonate use, and severe acidosis at presentation.
  • Acute Kidney Injury (AKI): Due to severe dehydration and hypovolemia.
  • Acute Respiratory Distress Syndrome (ARDS): Rare, but can be a complication of severe DKA or its underlying cause.
  • Rhabdomyolysis: Due to severe electrolyte imbalances and dehydration.
  • Vascular Thrombosis: Increased risk due to hyperosmolality and dehydration.
  • Mucormycosis: A rare but aggressive fungal infection, particularly in severe DKA with rhinocerebral involvement.
  • Aspiration Pneumonitis: Due to altered mental status and vomiting.
• Long-term:
  • Recurrent DKA: Common in patients with poor glycemic control, psychological issues, or non-adherence.
  • Worsening Glycemic Control: Repeated DKA episodes can lead to "beta-cell exhaustion" in some patients, making glycemic control harder.
  • Impact on Quality of Life: Frequent hospitalizations, fear of DKA, and chronic health issues.

Prognosis

• Factors Affecting Outcome:
  • Severity of DKA: Deeper acidosis, lower pH, and higher osmolality are associated with worse outcomes.
  • Age: Extremes of age (very young and very old) have higher mortality rates.
  • Level of Consciousness: Coma at presentation significantly worsens prognosis.
  • Presence of Cerebral Edema: High mortality and neurological morbidity.
  • Underlying Precipitating Illness: Severe infections (e.g., sepsis), MI, or stroke increase mortality.
  • Timeliness and Appropriateness of Management: Prompt and correct fluid, insulin, and electrolyte management is critical.
• Survival:
  • Mortality rates for DKA: Generally low in developed countries (0.2-2.5%), but significantly higher in elderly patients, those with severe comorbidities, or if cerebral edema develops (up to 20-40%).
  • Mortality rates for HHS: Higher than DKA (5-20%) due to greater dehydration, older age of patients, and more severe comorbidities.
  • Mortality rates for AKA: Can be significant if not promptly treated due to severe acidosis, electrolyte derangements, and associated alcohol-related complications.
• Quality of Life: Patients with recurrent DKA experience reduced quality of life, increased hospitalizations, and psychosocial burden. Good diabetes management can significantly improve long-term outcomes and quality of life.

Prevention

• Primary: Aimed at preventing the initial occurrence of DKA.
  • Early Diagnosis of Diabetes: Prompt recognition and initiation of insulin therapy in new-onset T1DM.
  • Comprehensive Diabetes Education: Essential for all patients with diabetes, particularly T1DM. This includes understanding the disease, insulin administration, blood glucose monitoring, and importance of adherence.
  • "Sick Day" Management Plan: Every patient with insulin-dependent diabetes should have a clear, written plan for managing blood glucose and ketones during illness, including:
    • Never omit insulin, even if not eating. Insulin dose may need adjustment.
    • Increase fluid intake (non-caloric or sugary if needed to avoid hypoglycemia).
    • Frequent blood glucose monitoring (every 2-4 hours).
    • Test for ketones (urine or blood BHB) during illness, especially if glucose >250 mg/dL.
    • When to seek medical attention (e.g., persistent vomiting, inability to keep fluids down, persistent high ketones, altered mental status).
  • Avoidance of Substance Abuse: Education on dangers of alcohol and drug abuse, especially for those with diabetes.
  • Careful Use of SGLT2 Inhibitors: Prescribe judiciously in patients with T1DM or risk factors for DKA. Educate patients on symptoms of euglycemic DKA and advise temporary cessation during illness/surgery.
• Secondary: Early detection and intervention to prevent progression to severe DKA.
  • Self-monitoring of Blood Ketones: Patients should be advised to test blood or urine ketones if blood glucose is consistently high (>250-300 mg/dL) or during illness (fever, nausea, vomiting).
  • Prompt Consultation: Encourage patients to contact their healthcare provider early if they develop symptoms of DKA or cannot manage their diabetes during illness.
• Tertiary: Preventing complications and recurrence after an episode of DKA.
  • Post-DKA Education Reinforcement: Review sick day plan, insulin adherence, and psychological support.
  • Optimization of Insulin Regimen: Adjust insulin doses and types to achieve optimal glycemic control (HbA1c <7.0% or individualized targets) and reduce variability.
  • Address Psychosocial Factors: Screen for depression, eating disorders, or other psychiatric conditions that contribute to insulin non-adherence. Referral to mental health professionals if needed.
  • Regular Follow-up: With an endocrinologist or diabetes specialist team.

Special Populations

• Pediatric:
  • Higher Risk of Cerebral Edema: This is the most feared complication, occurring in 0.5-1% of DKA episodes, with a mortality rate of 20-40%. Risk factors include new-onset DKA, younger age, severe acidosis (pH <7.0), rapid correction of glucose, rapid administration of hypotonic fluids, and bicarbonate use.
  • Fluid Management: Slower, more cautious fluid resuscitation (e.g., 10-20 mL/kg over 1-2 hours initial bolus, followed by replacement of estimated deficit over 24-48 hours). Avoid rapid drops in effective osmolality.
  • Sodium Monitoring: Close monitoring of corrected sodium levels is crucial; a failure of serum sodium to rise during treatment is a red flag for cerebral edema.
  • Insulin Dosing: Typically 0.05-0.1 U/kg/hour continuous IV infusion. Avoid initial insulin bolus.
  • Neurological Monitoring: Frequent neurological checks (GCS, pupil response) are paramount.
• Geriatric:
  • Increased Morbidity and Mortality: Higher rates due to comorbidities, polypharmacy, and diminished physiological reserves.
  • Fluid Management: Careful fluid resuscitation to avoid fluid overload, especially in patients with heart failure or renal dysfunction. Slower rates and closer monitoring of cardiac and renal status.
  • Underlying Cause: More likely to have a serious precipitating illness (e.g., MI, stroke, severe infection).
  • Cognitive Impairment: Can affect adherence to sick day rules and insulin regimens.
• Pregnancy:
  • Increased Risk of Euglycemic DKA: More common due to physiological changes, increased insulin resistance (later trimesters), and relative starvation during morning sickness.
  • Fetal Risk: DKA in pregnancy is associated with significant fetal morbidity and mortality (up to 20-30%), including spontaneous abortion, preterm labor, and fetal distress.
  • Management: Insulin requirements change dramatically. IV insulin infusion is preferred. Close maternal and fetal monitoring (fetal heart rate, contractions). Bicarbonate use is generally avoided due to theoretical fetal acidosis risk.
  • Potassium: Maintain K at higher end of normal range (e.g., 4-5 mEq/L) to prevent cardiac arrhythmias in the fetus.
• Comorbidities:
  • Renal Impairment: Adjust fluid rates and potassium/phosphate replacement carefully. Dialysis may be needed if severe AKI or hyperkalemia is refractory.
  • Heart Failure: Requires cautious fluid administration with close monitoring of fluid status (e.g., CVP, lung auscultation). Consider more concentrated insulin.
  • Sepsis/Infection: Prompt identification and aggressive antibiotic therapy for the underlying infection are crucial for DKA resolution.
  • Eating Disorders/Psychiatric Illness: These patients require significant psychosocial support and close follow-up after DKA resolution to prevent recurrence due to intentional insulin omission.

Clinical Pearls

• Diagnostic:
  • Don't rely solely on urine ketones: Urine dipsticks primarily detect acetoacetate. In early DKA, BHB is the predominant ketone, and a urine test may be falsely negative or mildly positive. Serum BHB is the gold standard.
  • Anion Gap is Key: A high anion gap metabolic acidosis is the hallmark. Calculate it consistently.
  • Corrected Sodium: Always calculate corrected sodium in hyperglycemia as it affects fluid choice. Na_corrected = Measured Na + 1.6 * [(Glucose - 100)/100].
  • Look for the Precipitant: Always actively search for the underlying cause of DKA (infection, MI, non-adherence, etc.).
• Treatment:
  • "Fluids First, Then Insulin": Rehydration is paramount to improve tissue perfusion and dilute glucose.
  • Potassium is the Most Dangerous Electrolyte: Hypokalemia during treatment is life-threatening. Always check K before starting insulin and monitor frequently.
  • Slow and Steady Glucose Correction: Aim for 50-75 mg/dL/hour drop. Too rapid a drop, especially in children, increases the risk of cerebral edema.
  • Do Not Stop Insulin When Glucose Normalizes: Continue IV insulin infusion, but switch fluids to D5NS or D10NS to provide glucose and allow ketosis to resolve (indicated by anion gap closure, not just glucose normalization).
  • Overlap IV and SC Insulin: To prevent rebound DKA, ensure at least 1-2 hours of overlap between the continuous IV insulin infusion and the first dose of subcutaneous insulin (especially long-acting basal insulin).
• Pitfalls:
  • Stopping IV fluids too soon: Patients remain significantly dehydrated even when glucose levels drop.
  • Not monitoring potassium frequently enough: Leading to severe hypokalemia.
  • Over-resuscitation with fluids: Leading to fluid overload, especially in vulnerable populations.
  • Using bicarbonate routinely: Worsens outcomes.
  • Not giving enough insulin: Resistance can be high initially, requiring dose escalation.
  • Failing to identify the precipitating cause: Leading to recurrent DKA.
  • Underestimating the total body potassium deficit: Even with normal initial serum K, patients are depleted.

Recent Updates

• SGLT2 Inhibitor Induced Euglycemic DKA (euDKA): Growing recognition and incidence. Patients on SGLT2 inhibitors (e.g., empagliflozin, canagliflozin, dapagliflozin) may present with DKA symptoms despite near-normal blood glucose levels. Awareness and screening for ketones are crucial in these patients, especially during illness or before surgery (where temporary cessation is recommended). Management principles are similar, but fluid management may differ slightly due to less pronounced hyperglycemia.
• Emphasis on Serum Beta-hydroxybutyrate (BHB): Guidelines increasingly emphasize the use of BHB for diagnosis and monitoring of DKA resolution, given its superiority over urine ketones.
• Individualized Fluid Management: Growing understanding that one-size-fits-all fluid protocols may not be optimal. Tailoring fluid type and rate based on corrected sodium, hydration status, and cardiac/renal function is gaining traction, especially in vulnerable populations.
• Transition Protocols: Continued refinement of protocols for transitioning from IV to subcutaneous insulin to minimize rebound hyperglycemia and ketosis.

Key References

• Guidelines:
  • American Diabetes Association (ADA) Standards of Medical Care in Diabetes: Annually updated guidelines, Section 11: Diabetes Management in Hospital, includes DKA/HHS. (e.g., Diabetes Care 2024;47(Suppl. 1):S118-S135)
  • American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) Clinical Practice Guidelines for Hyperglycemic Crises in Patients With Diabetes. (e.g., Endocr Pract. 2018;24(1):81-112)
  • International Society for Pediatric and Adolescent Diabetes (ISPAD) Clinical Practice Consensus Guidelines 2022: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. (e.g., Pediatr Diabetes. 2022 Oct;23(7):835-860)
• Studies:
  • Randomized controlled trials (RCTs) on fluid types (0.9% NS vs. balanced solutions) and rates in DKA, particularly in pediatric populations (e.g., Pediatric Emergency Care Applied Research Network (PECARN) trial on fluid management in pediatric DKA).
  • Observational studies and case series on SGLT2 inhibitor-induced DKA.
• Reviews:
  • UpToDate topics on DKA, HHS, and Alcoholic Ketoacidosis.
  • Review articles in major endocrinology or critical care journals on the pathophysiology and management of DKA.